Funding Strategy

Securing the right capital, from the right sources, and at the right moments is vital. Done correctly, a development journey is measured in years, rather than months. Without this approach, you can run out of cash if regulatory delays materialise, trial costs go over, or reimbursement negotiations extend beyond your initial projections. This way, it shows whether you’ve built a funding strategy that keeps in mind realistic timelines, structured capital to match development stages, and built in sufficient runway to survive any inevitable setbacks.

Building a regulatory buffer into the runway

Every financial model projects regulatory timelines that most prove optimistic, and MHRA post-Brexit processes, for example, will create unexpected delays. Founders who budget precisely for projected timelines without a buffer face cash exhaustion, just at the moment when approval seems imminent. Aim to build 6 to 12 months of additional runway beyond your regulatory timeline projections. If you project 18 months to CE mark approval, ensure funding extends to 30 months minimum.

Consider too that regulatory timelines compound across jurisdictions. Pursuing FDA approval, CE marking, and MHRA clearance simultaneously may sound efficient, but it can multiply complexity and extend timelines unpredictably. Your funding strategy should account for sequential rather than parallel regulatory processes (unless you've secured capital specifically for simultaneous multi-jurisdiction submissions).

When you're negotiating with regulators from a position of depleting cash reserves, you make compromised decisions that undermine both approval probability and commercial outcomes. A buffer isn't a luxury, it's survival insurance.

_{-Dame Kate Bingham, Managing Partner at SV Health Investors}

Bridging the reimbursement gap

Regulatory approval creates celebration. It shouldn't create complacency about cash requirements. The gap between regulatory clearance and meaningful commercial revenue spans 12 to 24 months while reimbursement coverage negotiations proceed. Health technology assessment processes in European markets, Medicare coverage determinations in the United States, and NHS commissioning decisions in the United Kingdom all require substantial time and evidence beyond regulatory approval.

Make sure to secure bridge financing for this reimbursement gap period. Structure this capital through convertible notes, venture debt, or dedicated equity tranches that fund commercial preparation without forcing premature scaling. Model your cash requirements carefully. Include costs for health economic studies demonstrating cost-effectiveness, key opinion leader engagement supporting coverage applications, payer negotiations, early commercial team salaries, and limited initial revenue from early-adopter institutions. This bridge period often requires £2-5 million beyond development capital.

Realistic trial budgeting

Clinical trial cost estimates are often too low. Initial budgets accounting for investigator fees, patient recruitment, and site costs miss substantial additional expenses that emerge during execution. Budget clinical trials at 2 to 3 times your initial estimate: this multiplier will accommodate hidden costs, including contract research organisation management fees, additional monitoring visits, protocol amendments, extended enrolment periods, statistical analysis, and patient retention activities.

Patient recruitment represents the most unpredictable trial cost element. Recruitment requires twice as long and costs twice as much as initially projected. Sites overestimate their patient populations. Inclusion criteria prove far more limiting than planned. Budget your recruitment costs conservatively (and include a contingency for extensions or additional sites).

Trial budgets that founders present in pitch decks consistently underestimate reality by factors of two to four. Investors will discount founder trial budgets automatically, so demonstrate you understand real trial economics by budgeting conservatively with line items for contingencies.

_{Professor Reza Razavi. Director Medical Engineering. King's College London}

Aligning with grant cycles

Government grants and non-dilutive funding represent the most founder-friendly capital available. Yet many companies miss opportunities because they don't align development timelines with application cycles. Innovate UK, NIH SBIR, European Commission Horizon programmes, and other grant sources operate on fixed application schedules. Missing a submission deadline by weeks can delay funding by six to twelve months. Map grant application deadlines early in your development planning and structure activities to align with these cycles.
Grant applications require substantial preparation time, so allocate 100 to 200 hours for competitive applications. Begin your prep work three to six months before submission deadlines to ensure quality applications rather than rushed submissions that reviewers reject. Consider too that grants fund specific technical milestones rather than general operating expenses. Structure your development plan around grant-fundable activities to include feasibility studies, prototype development, bench testing, and pilot clinical studies.

Match investors to your development stages

Different investor types align with different development stages: Angel investors provide early-stage capital for prototypes and proof-of-concept work. Venture capital firms fund clinical trials and regulatory submissions. Strategic corporate investors support scaling and commercialisation.

Target your angel investors when you've validated technical feasibility and need capital for prototype refinement, initial testing, and regulatory pathway definition (angels invest £25,000 to £250,000 individually or £500,000 to £2 million in syndicates). Pursue venture capital after achieving technical de-risking through prototype testing and preliminary evidence generation. VCs fund expensive clinical trials, regulatory submissions, and early commercialisation (they typically invest £2-15 million across series A and B rounds).

Engage strategic corporate investors when you've achieved regulatory approval or advanced clinical trial results that demonstrate commercial viability. Corporations invest to access innovation relevant to their strategic priorities. These will provide not just capital, but potential commercialisation partnerships, regulatory expertise, and eventual acquisition opportunities.

Timing capital increases strategically

Begin fundraising 12 to 18 months before cash depletion. This will allow for slower-than-expected processes, negotiation of favourable terms, and space to be selective with potential investor partners. Stage your capital increases around major value inflexion points to include prototype completion, successful bench testing, regulatory submissions, clinical trial initiation, positive interim results, regulatory approvals, and reimbursement coverage. Achieving these milestones between rounds only increases valuations and improves terms.

The funding strategy workshop

Your funding strategy will ensure sufficient resources to navigate development challenges without triggering premature compromises. This workshop aims to build a regulatory buffer accommodating realistic delays, secure reimbursement bridge capital, budget trials conservatively, and align development with grant cycles. These elements will transform funding from a reactive scramble into strategic orchestration and enable your innovation to reach the people who matter the most.

Waypoint checklist

Your path to a funding strategy should include the following:

• Your regulatory buffer should allow for FDA/CE delays with 6-12 months of extra runway.
• Secure bridge financing to cover 12-24 months of payer lag.
• Trial cost realism means budget 2-3 times more for pivotal trials than your initial estimates.
• A grant calendar will align non-dilutive funding with application cycles.
• Investor stage fit will target angels for prototypes, VCs for trials, and corporates for scaling.
• A robust funding strategy is all about timing and fit.